Second-generation TAVR valves from Medtronic, Edwards Lifesciences and Boston Scientific are all associated with similar seven-year outcomes, according to a new retrospective study out of Italy. 

The acquisition helps Teleflex expand its interventional and vascular portfolios. Biotronik, meanwhile, is shifting its focus toward implantable devices and digital healthcare. 

The Outsourcing Facilities Association, a Texas-based trade group, is alleging that supply issues still remain for Ozempic and Wegovy. The group believes the FDA has ignored those issues.

Google worked with AI specialists, cardiologists and even stunt performers to develop its new smartwatch feature.

The paclitaxel-coated device, already approved in Europe and other parts of the world, will be tested on more than 1,200 patients for a new international trial. If the study is a success, Medtronic hopes to gain regulatory approval in the United States and Japan. 

New technology now being considered by the FDA for approval can capture coronary inflammation on CCTA images and provide risk assessments. What could this mean for the future of cardiac care? We spoke to one researcher to learn more.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Kestra Medical Technologies, known for its wearable heart monitors and defibrillators, intends to sell 10 million common shares priced somewhere between $14 and $16 per share. 

Johnson & Johnson has reportedly had early discussions with potential buyers about its Cerenovus division of stroke products.

U.S. cardiology groups have worked together to propose the creation of a new American Board of Cardiovascular Medicine for certifying cardiologists. Now, after many months of waiting, a final decision is expected by the end of February. 

Researchers tracked data from more than 200 patients who underwent PCI from August 2020 to July 2022, sharing their findings in JACC: Cardiovascular Interventions.

The dispute was with Everly Health, a telemedicine provider contracted to fulfill orders for COVID-19 tests during the pandemic. Walgreens was accused of violating provisions of a service agreement. 

Fewer than one-third of primary care clinicians have a say in selecting the AI products their institutions expect them to fold into their clinical workflows. That’s a problem.